Sen. Van Wanggaard (R-Racine), chair of the Senate Committee on Judiciary and Public Safety, has scheduled a hearing on Tuesday, Nov. 24 at 10am in 411 South (New Room – Updated 11/19/2015) on his bipartisan cannabidiol legislation SB221, which would remove the need for a prescription to possess CBD in Wisconsin.
Previously, a hearing was held on the bipartisan Assembly version of the bill, AB228, on June 3, 2015. In 2014, lawmakers had passed 2013 Wisconsin Act 267, which legalized CBD with a prescription. This required federal approval and thus no patients were helped. This session’s legislation is intended to correct that.
AB228/SB221 is opposed by several state groups, the Wisconsin Medical Society (SMS), the WI Chiefs of Police Association and the Wisconsin Sheriffs and Deputy Sheriffs Association, according to the Government Accountability Board lobbying database.
Analysis by the Legislative Reference Bureau
Current law designates tetrahydrocannabinols (THC) as a schedule I controlled substance. Current law specifies that THC does not include cannabidiol (CBD oil) in a form without a psychoactive effect that is dispensed by a pharmacy or physician approved by the Controlled Substances Board or that is possessed by an individual who has documentation from a physician that the CBD oil is used for the treatment of a seizure disorder. This bill eliminates the requirement that, to be excluded from the definition of THC, the CBD oil must be dispensed by an approved pharmacy or physician or possessed by an individual with such documentation.